VivoSeq
Oncology

Metastatic Castration-Resistant Prostate Cancer

34

Pipeline Programs↗

18

Active Trials↗

20

Companies Involved↗

Metastatic Castration-Resistant Prostate Cancer is a moderately active landscape with 34 programs across 20 companies. The most active players are K36 Therapeutics, Inc., Fusion Pharmaceuticals Inc., Azurity Pharmaceuticals. 2 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

22/100

Mech. Concentration

19/100

Completion Rate

67/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

K36 Therapeutics, Inc.

1 program

Phase 1F

Fusion Pharmaceuticals Inc.

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2P

Prostate Oncology Specialists, Inc.

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 3BioNTech logo

BioNTech

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

30 of 32 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody13%Cell therapy13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 92% of 36 pipeline programs.

Analysis

Trial Status

21

clinical trials

Recruiting13 · 62%
Active, not recruiting5 · 24%
Completed2 · 10%
Suspended1 · 5%

Clinical Trials

Trial Activity

21 trials

Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study
Recruiting·Novartis logoNovartis·N/A·NCT06517719·500 enrolled
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
Recruiting·Pfizer logoPfizer·Phase 3·NCT06629779·900 enrolled
Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer
Recruiting·KK36 Therapeutics, Inc.·Phase 1·NCT07103018·144 enrolled
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting·Roche logoRoche·Phase 2·NCT07287150·100 enrolled
A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
Recruiting·Novartis logoNovartis·N/A·NCT06514521·278 enrolled
A Single Arm Open-label, Phase II Study of Sipuleucel-T With Bipolar Androgen Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Recruiting·YYale University·Phase 2·NCT06100705·26 enrolled
A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07611110·670 enrolled
Addition of Darolutamide to First Line Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Randomized Open Label Phase II Trial
Recruiting·SSwiss Cancer Institute·Phase 2·NCT06401980·162 enrolled
PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617
Recruiting·UUniversity of Utah·Phase 2·NCT06568562·32 enrolled
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06764485·960 enrolled
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
Recruiting·BioNTech logoBioNTech·Phase 3·NCT07365995·736 enrolled
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Recruiting·Amgen logoAmgen·Phase 3·NCT07213674·750 enrolled
A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Recruiting·SSyncromune, Inc.·Phase 2·NCT06533644·91 enrolled
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Active, not recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT02861573·1,200 enrolled
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Active, not recruiting·FFusion Pharmaceuticals Inc.·Phase 2·NCT06909825·85 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)